References
- 1. Bryckaert M, Rosa JP, Denis CV, Lenting PJ- Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015;72:307-326.10.1007/s00018-014-1743-8
- 2. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA- N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111:3042-3049.10.1182/blood-2007-06-095042
- 3. Reid P, Holen I – Pathophysiological role of osteoprotegerin (OPG). European Journal of Cell Biology. 2009;88:1-17.10.1016/j.ejcb.2008.06.004
- 4. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD - Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5:1956-1962.10.1111/j.1538-7836.2007.02681.x
- 5. Zannettino AC, Holding CA, Diamond P et al - Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005, 204:714-723.10.1002/jcp.20354
- 6. Rutten B, Maseri A, Cianflone D - Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: A multicenter and multiethnic study. Eur Heart J Acute Cardiovasc Care. 2015;4:64-74.10.1177/2048872614534388
- 7. Hosbond SE, Poulsen TS, Diederichsen ACP, Nybo M, Rasmussen LM, Mickley H- Osteoprotegerin as a marker of atherosclerosis: A systematic update. Scandinavian Cardiovascular Journal. 2012;46:203-211.10.3109/14017431.2012.685491
- 8. Ali Z, Ellington AA, Mosley TH, Jr., Kullo IJ: Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis. 2009;206:575-580.10.1016/j.atherosclerosis.2009.03.032
- 9. Vinholt PJ, Overgaard M, Diederichsen AC, Mickley H, Poulsen TS, Sand NP, Nybo M, Rasmussen LM: An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma. Thromb Res. 2013,131:396-400.10.1016/j.thromres.2013.03.001